Suppr超能文献

在乳腺癌细胞系中用 Affimer 标记突变雌激素受体。

Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line.

机构信息

Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois; Center for Physics of Living Cells, University of Illinois at Urbana-Champaign, Urbana, Illinois.

School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.

出版信息

Biophys J. 2022 Oct 4;121(19):3651-3662. doi: 10.1016/j.bpj.2022.06.028. Epub 2022 Jun 30.

Abstract

Mutations of the intracellular estrogen receptor alpha (ERα) is implicated in 70% of breast cancers. Therefore, it is of considerable interest to image various mutants (L536S, Y537S, D538G) in living cancer cell lines, particularly as a function of various anticancer drugs. We therefore developed a small (13 kDa) Affimer, which, after fluorescent labeling, is able to efficiently label ERα by traveling through temporary pores in the cell membrane, created by the toxin streptolysin O. The Affimer, selected by a phage display, predominantly labels the Y537S mutant and can tell the difference between L536S and D538G mutants. The vast majority of Affimer-ERαY537S is in the nucleus and is capable of an efficient, unrestricted navigation to its target DNA sequence, as visualized by single-molecule fluorescence. The Affimer can also differentiate the effect of selective estrogen receptor modulators. More generally, this is an example of a small binding reagent-an Affimer protein-that can be inserted into living cells with minimal perturbation and high efficiency, to image an endogenous protein.

摘要

细胞内雌激素受体 alpha(ERα)的突变与 70%的乳腺癌有关。因此,对活癌细胞系中各种突变体(L536S、Y537S、D538G)进行成像具有相当大的意义,特别是作为各种抗癌药物的功能。因此,我们开发了一种小的(13 kDa)Affimer,在荧光标记后,它能够通过链球菌溶血素 O 产生的暂时细胞膜孔有效地标记 ERα。该 Affimer 通过噬菌体展示进行选择,主要标记 Y537S 突变体,并且能够区分 L536S 和 D538G 突变体。绝大多数 Affimer-ERαY537S 位于细胞核内,并且能够高效、不受限制地导航到其靶 DNA 序列,如单分子荧光所可视化的那样。该 Affimer 还可以区分选择性雌激素受体调节剂的作用。更一般地说,这是一种可以以最小的干扰和高效率插入活细胞以对内源性蛋白质进行成像的小型结合试剂-Affimer 蛋白的示例。

相似文献

1
Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line.
Biophys J. 2022 Oct 4;121(19):3651-3662. doi: 10.1016/j.bpj.2022.06.028. Epub 2022 Jun 30.
2
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Breast Cancer Res. 2021 May 12;23(1):54. doi: 10.1186/s13058-021-01431-w.
4
Cadmium activation of wild-type and constitutively active estrogen receptor alpha.
Front Endocrinol (Lausanne). 2024 Aug 9;15:1380047. doi: 10.3389/fendo.2024.1380047. eCollection 2024.
5
Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Endocrinology. 2018 Jan 1;159(1):285-296. doi: 10.1210/en.2017-00693.
6
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Breast Cancer Res Treat. 2020 Apr;180(3):611-622. doi: 10.1007/s10549-020-05564-y. Epub 2020 Feb 17.
7
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Breast Cancer Res. 2017 May 23;19(1):60. doi: 10.1186/s13058-017-0851-4.
8
A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.
Biochem Pharmacol. 2021 Jun;188:114583. doi: 10.1016/j.bcp.2021.114583. Epub 2021 Apr 27.
10
Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Mol Cell Endocrinol. 2019 Jan 15;480:107-121. doi: 10.1016/j.mce.2018.10.020. Epub 2018 Oct 31.

引用本文的文献

1
A Stronger IMPACT on Career Development for Early- and Mid-career Faculty.
J Endocr Soc. 2024 Nov 14;8(12):bvae191. doi: 10.1210/jendso/bvae191. eCollection 2024 Oct 29.

本文引用的文献

1
Structure of an AMPK complex in an inactive, ATP-bound state.
Science. 2021 Jul 23;373(6553):413-419. doi: 10.1126/science.abe7565.
2
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.
Nat Commun. 2021 Jun 30;12(1):4045. doi: 10.1038/s41467-021-24316-0.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
TALEN outperforms Cas9 in editing heterochromatin target sites.
Nat Commun. 2021 Jan 27;12(1):606. doi: 10.1038/s41467-020-20672-5.
7
Hormonal modulation of ESR1 mutant metastasis.
Oncogene. 2021 Feb;40(5):997-1011. doi: 10.1038/s41388-020-01563-x. Epub 2020 Dec 15.
8
27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
Cancer Lett. 2020 Nov 28;493:266-283. doi: 10.1016/j.canlet.2020.08.020. Epub 2020 Aug 28.
9
Cytosolic delivery of proteins by cholesterol tagging.
Sci Adv. 2020 Jun 19;6(25):eabb0310. doi: 10.1126/sciadv.abb0310. eCollection 2020 Jun.
10
Affimers as an alternative to antibodies for protein biomarker enrichment.
Protein Expr Purif. 2020 Oct;174:105677. doi: 10.1016/j.pep.2020.105677. Epub 2020 May 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验